Editas Medicine (EDIT) has issued an update.
Editas Medicine, Inc. has unveiled promising new data from clinical trials of its gene-editing therapy, Reni-cel, for severe sickle cell disease and transfusion-dependent beta thalasemia. Patients in the RUBY trial experienced no vaso-occlusive events and significant improvements in hemoglobin levels, while those in the EdiTHAL trial achieved transfusion independence with robust hemoglobin increases. Both trials reported successful engraftment, no serious adverse events, and a safety profile in line with current gene therapy standards.
For a thorough assessment of EDIT stock, go to TipRanks’ Stock Analysis page.
